Welcome to our dedicated page for Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of news (Ticker: TAK), a resource for investors and traders seeking the latest updates and insights on Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of stock.
Takeda Pharmaceutical Company Limited (NYSE: TAK), a Japanese multinational corporation, stands as Asia's largest and one of the globe's top 20 pharmaceutical giants by revenue. Headquartered in Tokyo, Takeda operates across approximately 80 countries, merging American and British roots into its vast global presence.
With a revenue of JPY 4.3 trillion in fiscal 2023, Takeda dedicates its efforts predominantly to five therapeutic areas: oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which collectively generate more than 80% of its revenue. Takeda’s global footprint is diversified, with 50% of its revenue originating from the US, 20% from Japan, and another 20% from Europe and Canada.
Noteworthy for its robust pipeline and commitment to innovation, Takeda partners with various organizations to push the boundaries of medical research. A recent highlight includes a joint venture with Astellas Pharma Inc. and Sumitomo Mitsui Banking Corporation. This collaboration aims to incubate early drug discovery programs, striving to transition academic breakthroughs into practical medical treatments.
Moreover, Takeda's strategic partnership with Neurocrine Biosciences to develop NBI-1065845, an investigational treatment for major depressive disorder, showcases its dedication to addressing unmet medical needs. The positive Phase 2 results of the SAVITRI™ study underline the potential of NBI-1065845 to provide hope for patients with inadequate responses to existing treatments.
Takeda's philosophy focuses on creating a healthier world through life-transforming treatments in its core areas. Their values-based, R&D-driven approach has sustained their leadership in the pharmaceutical sector for over two centuries.
Takeda has launched the CDPATH™ program, a personalized prognostic tool designed for Crohn's disease patients in the U.S. This tool predicts the risk of developing serious complications within three years using blood tests, and it's offered at no cost to eligible adult patients. The program aims to facilitate shared decision-making between patients and healthcare providers by integrating patient-specific markers with clinical assessments. CDPATH is available through over 2,500 locations nationwide, enhancing patient-centered care for over three million people affected by inflammatory bowel disease.
Takeda has launched four new partnerships under its Global Corporate Social Responsibility (CSR) Program, contributing a total of
Takeda announced that its dengue vaccine, QDENGA (TAK-003), has been approved by the
NextRNA Therapeutics announces the appointment of Dominique Verhelle, PhD, MBA, as CEO, effective immediately. Verhelle, a co-founder of the company, has spearheaded its scientific and corporate strategy since its inception. Under her leadership, NextRNA secured $56M in financing to advance its unique platform aimed at developing small molecule drugs targeting non-coding RNA interactions. Additionally, Jason Katz has been appointed as VP and Head of Drug Discovery, bringing extensive drug discovery experience from IFM Therapeutics and Merck.
Takeda reported its Q1 FY2022 financial results with core revenue growth of +8.3% at constant exchange rates (CER) and a core operating profit growth of +17%. Reported revenues reached
Takeda announced that its Phase 3 clinical trial, ADVANCE-1, evaluating HYQVIA for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), met its primary endpoint. The treatment reduced relapse rates significantly compared to placebo (9.7% vs 31.4%; p-value = 0.0045). The trial involved 132 adult patients previously on IVIG therapy. Takeda plans to submit regulatory applications in the US and EU for HYQVIA in fiscal year 2022.
Takeda Pharmaceutical Company Limited has submitted its Corporate Governance Report to the Tokyo Stock Exchange, adhering to TSE regulations. This report, rooted in the revised Corporate Governance Code effective as of June 11, 2021, highlights a diverse Board of Directors with a composition of 4 internal and 11 independent external directors. The report emphasizes increased transparency and independence in governance, with advisory committees staffed entirely by external directors. The full report can be accessed on Takeda’s website and the Japan Exchange Group’s platform.
Takeda reported positive results from the Phase 3 SPRING study of TAKHZYRO, a treatment for hereditary angioedema (HAE) in children aged 2 to <12 years. The study demonstrated a 94.8% reduction in HAE attacks over 52 weeks compared to baseline. Notably, 76.2% of patients were attack-free during the treatment, with an average of 99.5% attack-free days. The results align with the efficacy and safety profile seen in adults. Takeda plans to initiate global regulatory filings in fiscal year 2022 to expand TAKHZYRO's indication for younger patients.
Takeda (TAK) and Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced promising results from the Phase 2 AROAAT-2002 study of fazirsiran for liver disease due to alpha-1 antitrypsin deficiency (AATD). Key findings include a 58% fibrosis regression in treated patients, an 83% median reduction in Z-AAT accumulation in the liver, and a 69% reduction in histologic globule burden. Fazirsiran aims to tackle AATD's liver manifestations, with plans for a Phase 3 study on the horizon. The collaboration has received Breakthrough Therapy and Orphan Drug designations from the FDA.
Takeda has signed a 15-year lease with BioMed Realty for 600,000 square feet of R&D and office space in Kendall Square, Massachusetts. The new facility will enhance Takeda's research capabilities and support the company's shift towards flexible workspaces. Construction is set to begin in 2023, with occupation expected by 2026. This move aligns with Takeda's goal of achieving net-zero greenhouse gas emissions and reflects its commitment to innovation and sustainability while expanding its presence in a prominent life sciences hub.
FAQ
What is the current stock price of Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of (TAK)?
What is the market cap of Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of (TAK)?
What are Takeda Pharmaceutical's core therapeutic areas?
Where is Takeda Pharmaceutical headquartered?
What recent collaborations has Takeda Pharmaceutical entered into?
How diversified is Takeda's revenue geographically?
What was Takeda's revenue in fiscal 2023?
Who can benefit from Takeda's new drug NBI-1065845?
What is the focus of Takeda’s joint venture with Astellas and Sumitomo Mitsui?
How long has Takeda been in the pharmaceutical industry?
In how many countries does Takeda operate?
How does Takeda contribute to the field of major depressive disorder treatment?
